Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Doris Lippman

Registered Nurse, Psychiatric/Mental Health, Adult Westport, CT Nurse Practitioner

NPI 1538600051 CMS profile 10669629

18 Sylvan Road South, Westport, CT 06880

Open in the dashboard

General payments

$3,218

71 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Doris Lippman of Westport, CT is reported in the CMS Open Payments database as having received $3,218 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Registered Nurse, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $429 12
2024 General $669 12
2023 General $954 18
2022 General $622 13
2021 General $543 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Doris Lippman
  • Registered Nurse, Psychiatric/Mental Health, Adult median
  • Middle half of Registered Nurse, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Doris Lippman were reported at $429. Among 96 Registered Nurse, Psychiatric/Mental Health, Adult profiles paid that year, the median was $121 and the middle half received between $39 and $265.

Show as a table
Year Doris Lippman Registered Nurse, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $543 $108 $31–$328 $132
2022 $622 $99 $22–$306 $149
2023 $954 $99 $43–$313 $160
2024 $669 $119 $30–$319 $164
2025 $429 $121 $39–$265 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $1,227 24 payments
  2. AbbVie, Inc. $983 14 payments
  3. GlaxoSmithKline, LLC. $229 7 payments
  4. Neurocrine Biosciences, Inc. $138 3 payments
  5. Corium, Inc. $111 1 payment
  6. Supernus Pharmaceuticals, Inc. $111 5 payments
  7. UCB, Inc. $110 4 payments
  8. Vanda Pharmaceuticals Inc. $84 4 payments
  9. Mallinckrodt Hospital Products Inc. $75 3 payments
  10. Almatica Pharma LLC $53 2 payments
  11. Other $97 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,218 71 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA Psychiatry $904 17 payments
  2. VRAYLAR $858 13 payments
  3. CAPLYTA Psychiatry $323 7 payments
  4. BENLYSTA $229 7 payments
  5. INGREZZA $138 3 payments
  6. SKYRIZI $125 1 payment
  7. Azstarys $111 1 payment
  8. Cimzia $110 4 payments
  9. QELBREE $87 4 payments
  10. FANAPT $84 4 payments
  11. Other $279 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

332

Median for Registered Nurse: 109

Drug cost

$6,711

Median for Registered Nurse: $4,454

Branded share of claims

26.8%

Median for Registered Nurse: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Chlorpromazine Hcl Generic 11 $3,337
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 29 $996
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 60 $800
Clonazepam Generic 60 $611
Gabapentin Generic 11 $285
Alprazolam Generic 48 $228
Lorazepam Generic 37 $181
Temazepam Generic 18 $151
Zolpidem Tartrate Generic 43 $92
Sertraline Hcl Generic 15 $31

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $295
$295 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $138
$138 — —
VRAYLAR
  • AbbVie, Inc. $125
$125 — —
Azstarys
  • Corium, Inc. $111
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Psychiatric/Mental Health, Adult in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record